Matthew B. Palmer, MD, PhD
Pathology and Laboratory Medicine
Accepting new patients
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Penn Medicine Provider

About me

  • Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Emory University
  • Residency: Yale-New Haven Hospital
  • Fellowship: Yale-New Haven Hospital

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Palmer is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Dhanunjay Mukhi, Lakshmi Prasanna Kolligundla, Tomohito Doke, Magaiver Andrade- Silva, Hongbo Liu, Matthew Palmer, Katalin Susztak The actin and microtubule network regulator WHAMM is identified as a key kidney disease risk gene. , Cell Reports, 44(4): 2025


Aguila T, Madan R, Palmer MB, Derk CT Zebra Bodies in Kidney Biopsy: Drug-Induced Phospholipidosis in a Patient With Systemic Lupus Erythematosus. , Journal of Rheumatology: 2025


Liu H, Abedini A, Ha E, Ma Z, Sheng X, Dumoulin B, Qiu C, Aranyi T, Li S, Dittrich N, Chen HC, Tao R, Tarng DC, Hsieh FJ, Chen SA, Yang SF, Lee MY, Kwok PY, Wu JY, Chen CH, Khan A, Limdi NA, Wei WQ, Walunas TL, Karlson EW, Kenny EE, Luo Y, Kottyan L, Connolly JJ, Jarvik GP, Weng C, Shang N, Cole JB, Mercader JM, Mandla R, Majarian TD, Florez JC, Haas ME, Lotta LA; Regeneron Genetics Center‡; GHS-RGC DiscovEHR Collaboration§; Drivas TG; Penn Medicine BioBank¶; Vy HMT, Nadkarni GN, Wiley LK, Wilson MP, Gignoux CR, Rasheed H, Thomas LF, Åsvold BO, Brumpton BM, Hallan SI, Hveem K, Zheng J, Hellwege JN, Zawistowski M, Zöllner S, Franceschini N, Hu H, Zhou J, Kiryluk K, Ritchie MD, Palmer M, Edwards TL, Voight BF, Hung AM, Susztak K Kidney multiome-based genetic scorecard reveals convergent coding and regulatory variants. , Science, 387(6734): 2025,4753


Sato S, Miwa T, Gullipalli D, Golla M, Mohammadyari E, Zhou L, Palmer M, Song WC. Improved therapeutic efficacy of a bifunctional anti-C5 mAb-FH SCR1-5 fusion protein over anti-C5 mAb in an accelerated mouse model of C3 glomerulopathy. , Immunohorizons, 9(3): 2025


Abedini A, Levinsohn J, Klötzer KA, Dumoulin B, Ma Z, Frederick J, Dhillon P, Balzer MS, Shrestha R, Liu H, Vitale S, Bergeson AM, Devalaraja-Narashimha K, Grandi P, Bhattacharyya T, Hu E, Pullen SS, Boustany-Kari CM, Guarnieri P, Karihaloo A, Traum D, Yan H, Coleman K, Palmer M, Sarov-Blat L, Morton L, Hunter CA, Kaestner KH, Li M, Susztak K. Single-cell multi-omic and spatial profiling of human kidneys implicates the fibrotic microenvironment in kidney disease progression. , Nature Genetics, 56(8): 2024,1712-1724


Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, Drake CG, Signoretti S, Akgul M, Baniak N, Li-Ning E, Palmer MB, Emamekhoo H, Adra N, Kaimakliotis H, Ged Y, Pierorazio PM, Abel EJ, Bilen MA, Ogan K, Moon HH, Ramaswamy KA, Singer EA, Mayer TM, Lohrey J, Margulis V, Gills J, Delacroix SE, Waples MJ, James AC, Wang P, Choueiri T, Michaelson MD, Kapoor A, Heng DY, Shuch B, Leibovich BC, Lara PN, Manola J, Maskens D, Battle D, Uzzo R, Bratslavsky G, Haas NB, Carducci MA. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. , Lancet Oncology, 25(8): 2024,1038-1052


Yan Y, Liu H, Abedini A, Sheng X, Palmer M, Li H, Susztak K. Unraveling the epigenetic code: human kidney DNA methylation and chromatin dynamics in renal disease development. , Nature Communications, 15(1): 2024,873


Murphy JD, Caza TN, Cassol CA, Storey A, Ambruzs JM, Boils C, Walker PD, Sharma S, Messias N, Hennigar R, Andeen NK, VanBeek C, Palmer M, Sankar L, Sanghi P, Dinesh K, Dicker L, Urisman A, Larsen CP. Clinicopathologic Features of Antibrush Border Antibody Disease. , Kidney International Reports, 9(2): 2023,370-382


Matthew B Palmer; Virginie Royal; J. Charles Jennette; Abigail R. Smith; Qian Liu; Josephine M. Ambruzs; Nicole K. Andeen; Vivette D. D’Agati; Agnes B. Fogo; Joseph Gaut; Rasheed A. Gbadegesin; Larry A. Greenbaum; Jean Hou; Margaret E Helmuth; Richard A. Lafayette; Helen Liapis; Bruce Robinson; Michael B. Stokes; Katherine Twombley; Hong Yin; Cynthia C. Nast; for the CureGN Consortium Cure Glomerulonephropathy Pathology Classification and Core Scoring Criteria, Reproducibility, and Clinicopathologic Correlations , Glomerular Diseases, 3(1): 2023,248-257


Nova-Camacho LM, Acosta AM, Trpkov K, Sangoi AR, Pierre A, Chou A, Yilmaz A, Morini A, Rodrigues Â, Fletcher CDM, Perez-Montiel D, Maclean F, Contreras F, Queipo FJ, Muñiz Unamunzaga G, Mesa H, de Torres I, Ruiz I, Alvarado-Cabrero I, Lobo J, Schwartz L, Cheng L, Akgul M, García-Martos M, Palmer MB, Aron M, Raspollini MR, Manrique Celada M, Hwang M, Idrees MT, Rioux-Leclercq N, Zalles N, Vergara N, Lal P, Wobker S, Kammerer-Jacquet SF, Prendeville S, Tilmant T, Ulbright TM, Verkarre V, Collins K, Williamson SR, Panizo A. Metastatic solid tumors to the testis: a clinicopathologic evaluation of 157 cases from an international collaboration. , Human Pathology, 139: 2023,37-46